1. Randomised, double-blind, phase III study comparing the infliximab biosimilar, PF-06438179/GP1111, with reference infliximab: efficacy, safety and immunogenicity from week 30 to week 54. Issue 1 (28th March 2019) Authors: Alten, Rieke; Batko, Bogdan; Hala, Tomas; Kameda, Hideto; Radominski, Sebastiao C; Tseluyko, Vira; Babic, Goran; Cronenberger, Carol; Hackley, Sarah; Rehman, Muhammad; von Richter, Oliver; Zhang, Min; Cohen, Stanley Journal: RMD open Issue: Volume 5:Issue 1(2019) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗